Amneal Pharmaceuticals, Inc.
AMRX
$10.83
$0.838.25%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 9.81% | 13.42% | 16.73% | 12.32% | 12.37% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.81% | 13.42% | 16.73% | 12.32% | 12.37% |
| Cost of Revenue | 7.86% | 13.64% | 16.26% | 11.30% | 10.90% |
| Gross Profit | 13.23% | 13.05% | 17.55% | 14.14% | 15.07% |
| SG&A Expenses | 8.62% | 9.53% | 10.88% | 8.02% | 10.04% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -3,060.69% | -2,853.76% | 108.79% | 103.84% | 104.33% |
| Total Operating Expenses | 9.00% | 12.77% | 15.24% | 11.01% | 9.78% |
| Operating Income | 15.40% | 18.03% | 28.33% | 22.30% | 34.26% |
| Income Before Tax | 177.24% | 154.52% | -36.61% | -446.56% | -883.39% |
| Income Tax Expenses | 116.47% | 83.46% | 123.18% | 822.52% | 414.37% |
| Earnings from Continuing Operations | 138.47% | 126.95% | -51.63% | -477.87% | -1,274.52% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -15.58% | 6.03% | -21.94% | -33.53% | -209.31% |
| Net Income | 101.93% | 92.27% | -39.16% | -1,886.83% | -8,426.17% |
| EBIT | 15.40% | 18.03% | 28.33% | 22.30% | 34.26% |
| EBITDA | 12.77% | 13.01% | 16.71% | 10.84% | 14.76% |
| EPS Basic | 101.59% | 92.50% | -22.41% | -1,134.95% | -4,181.38% |
| Normalized Basic EPS | -26.91% | -581.91% | -291.34% | -92.37% | -87.58% |
| EPS Diluted | 101.34% | 92.56% | -20.20% | -1,311.84% | -2,572.65% |
| Normalized Diluted EPS | -40.36% | -591.58% | -290.84% | -92.37% | -87.59% |
| Average Basic Shares Outstanding | 22.67% | 44.32% | 75.61% | 91.28% | 66.63% |
| Average Diluted Shares Outstanding | 22.94% | 45.85% | 75.36% | 90.82% | 68.83% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |